SCHEMBL4374380

SCHEMBL4374380

Cc1ccc(S(=O)(=O)C(C#N)=Cc2ccc(-c3sccc3C#N)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 9/20 0.59
▸ PKM P14618 3/20 0.59
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ MAPT P10636 5/20 0.43
▸ LMNA P02545 2/20 0.43
▸ PTGS2 P35354 2/20 0.41
▸ ALDH1A1 P00352 8/20 0.41
▸ KDM4E B2RXH2 5/20 0.41
▸ RECQL P46063 1/20 0.41
▸ MEN1 O00255 5/20 0.41
▸ KMT2A Q03164 5/20 0.41
▸ GAA P10253 2/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ ALOX12 P18054 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ ALPG P10696 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4374377 1.00 HPGD (0.59) HPGDPKML3MBTL1MAPTLMNA
SCHEMBL8288499 0.86 HPGD (0.58) HPGDPKML3MBTL1MAPTLMNA
SCHEMBL4372999 0.86 HPGD (0.58) HPGDPKML3MBTL1MAPTLMNA
SCHEMBL4373172 0.76 HPGD (0.71) HPGDPKML3MBTL1MAPTLMNA
SCHEMBL4373169 0.76 HPGD (0.71) HPGDPKML3MBTL1MAPTLMNA
SCHEMBL11744761 0.76 PKM (0.74) HPGDPKML3MBTL1MAPTLMNA
SCHEMBL11744756 0.76 PKM (0.74) HPGDPKML3MBTL1MAPTLMNA
SCHEMBL8315343 0.75 PTGS2 (0.44) HPGDL3MBTL1PTGS2ALDH1A1KDM4E
SCHEMBL12566589 0.70 HPGD (0.60) HPGDPKML3MBTL1MAPTLMNA
SCHEMBL4070530 0.69 HPGD (0.57) HPGDPKML3MBTL1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7625932-B2 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-12-01 — — US disclosed
EP-1670757-B1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2009-05-06 — — EP disclosed
US-20070066573-A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY 2007-03-22 — — US disclosed
EP-1670757-A1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2006-06-21 — — EP disclosed
WO-2005040110-A1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2005-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066573-A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors GRIN1, GRIN3A, GRIK5 HPGD 1113/4885PKM 1246/4885L3MBTL1 4765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback